Review: Systemic therapy for advanced renal cell carcinoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Therapeutic Advances in Medical Oncology

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1758834009338430PMID 21789110PMCID PMC3125990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.

  2009cited by this paper
• Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer

  2009cited by this paper
• Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

  2009cited by this paper
• Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

  2009cited by this paper
• Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

  2009cited by this paper
• Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

  2009cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.

  2008cited by this paper
• Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.

  2008cited by this paper
• Temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma: Preliminary results from the Austrian Compassionate Use Program

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)

  2008cited by this paper
• Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

  2008cited by this paper
• Efficacy and safety of first-line bevacizumab (BEV) plus interferon-{alpha}2a (IFN) in patients (pts) >=65 years with metastatic renal cell carcinoma (mRCC)

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

  2008influential reference
• Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

  2008cited by this paper
• Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

  2008cited by this paper
• Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

  2008cited by this paper
• Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

  2008cited by this paper
• Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

  2008cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

  2007cited by this paper
• Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis

  2007cited by this paper
• The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.

  2007cited by this paper
• Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681

  2007cited by this paper
• Renal-cell carcinoma--molecular pathways and therapies.

  2007cited by this paper
• The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment

  2007cited by this paper
• VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib

  2007cited by this paper
• Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

  2007cited by this paper
• Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results

  2007cited by this paper
• A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies

  2007cited by this paper
• Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

  2007cited by this paper
• Rapsody: randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α 2A (IFN) in metastatic renal cell carcinoma (MRCC). GOIRC study 0681

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

  2007cited by this paper
• Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

  2007cited by this paper
• Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis

  2007cited by this paper
• Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• The Biology of Cancer

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.

  2006cited by this paper
• Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

  2005cited by this paper
• Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

  2005cited by this paper
• Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

  2005cited by this paper
• Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

  2005cited by this paper
• Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

  2005cited by this paper
• Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

  2005cited by this paper
• Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

  2004cited by this paper
• Prognostic Factors in Patients with Advanced Renal Cell Carcinoma

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma

  2004cited by this paper
• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

  2003cited by this paper
• Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors

  2003cited by this paper
• Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

  2003cited by this paper
• Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• Randomized discontinuation design: application to cytostatic antineoplastic agents.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Sarcomatoid Differentiation in Renal Cell Carcinoma: A Study of 101 Cases

  2001cited by this paper
• Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

  2001cited by this paper
• Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.

  2001cited by this paper
• Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

  2001cited by this paper
• Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

  1999cited by this paper
• Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.

  1995cited by this paper
• Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer.

  1989cited by this paper
• Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma.

  1989cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper

• A Novel Hybrid Model of Flying Geese Optimization and Attention-LSTM for Predicting Survival Outcomes in Clear Cell Renal Cell Carcinoma

  2026cites this paper
• Cytopathological Study of the Circulating Tumor Cells filtered from the Cancer Patients’ Blood using Hydrogel-based Cell Block Formation

  2018cites this paper
• Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study

  2017cites this paper
• Prognostic Benefit of Surgical Management of Renal Cell Carcinoma Invading the Inferior Vena Cava

  2017cites this paper
• Formal synthesis of (-)-englerin A and cytotoxicity studies of truncated englerins.

  2012cites this paper
• Bayesian Enrichment Strategies for Randomized Discontinuation Trials

  2012cites this paper
• Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.

  2011cites this paper